Remove Assay Development Remove Research Remove White Paper
article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

For these reasons and others, many biotech and pharmaceutical companies – along with government research labs and academic institutions – rely on contract research organizations (CROs) for drug discovery services. Three common questions regarding the challenges when considering outsourcing partners for drug discovery.

article thumbnail

OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer

FDA Law Blog: Drug Discovery

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC). By Holly N.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time

Agency IQ

In 2019, the advocacy organization, Friends of Cancer Research (FOCR) organized a multi-stakeholder initiative comprised of industry, government, and academia to find out. In parallel, FOCR developed a white paper that provided an overview of the potential regulatory applications for ctDNA in oncology.

FDA 40
article thumbnail

Brochure: Dynabeads manual and automated SARS-CoV-2 enrichment

The Pharma Data

Cell culture for virus isolation also remains a useful method for growing and studying viruses in research settings especially in the characterization of novel pathogenic viruses like SARS-CoV-2 although this requires more advanced containment facilities such as biosafety level 3 (BSL-3).

Virus 52